Drugs / GAL-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06659549 | Jan 2025 → Mar 2027 expected | dry age related macular degeneration | Galimedix Therapeutics Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-03-12 | Galimedix Therapeutics Inc | Results Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation galimedix.com ↗
Phase 1 results show the compound to be clinically safe and well-tolerated, with a pharmacokinetic profile supporting advancing to Phase 2 |
| 2025-12-04 | Galimedix Therapeutics Inc | Results Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025 galimedix.com ↗
GAL-101 was safe and well tolerated, with no dose-limiting adverse events observed |
| 2025-09-12 | Galimedix Therapeutics Inc | Results Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator galimedix.com ↗
In the trial, GAL-101 was shown to be well tolerated and clinically safe, with no serious adverse events (SAEs) observed. |
| 2025-05-06 | Galimedix Therapeutics Inc | Results Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator galimedix.com ↗
The results showed that GAL-101 was well tolerated with a highly favorable safety profile. |
| 2019-10-08 | Galimedix Therapeutics Inc | Results Galimedix Therapeutics, Inc. To Present at Ophthalmology Innovation Summit During the American Academy of Ophthalmology Meeting galimedix.com ↗
New Preclinical Data Demonstrate Restoration of Lost Neuronal Function With GAL-101 in vitro, Could Translate into a Better Vision in Glaucoma and dry AMD Patients |
| 2019-05-08 | Galimedix Therapeutics Inc | Results Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models galimedix.com ↗
Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today presented data demonstrating its novel, first-in-class, investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. |
| 2019-02-06 | Galimedix Therapeutics Inc | Results Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference galimedix.com ↗
The presentation also included positive safety and tolerability data from the company’s Phase 1 study in both healthy and glaucoma patients. |
| 2018-11-08 | Galimedix Therapeutics Inc | Results New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects galimedix.com ↗
Even after a thousand-fold dilution below predicted therapeutic levels, it prevented the formation of these toxic oligomers and even reversed their toxic effects by rapidly capturing the misfolded proteins into harmless “blobs” that continued their work even after the drug dropped below minimal levels. |
All press releases naming this drug 14 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAL-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06659549 ↗ |
| Route | Other | “GAL-101 is given as eyedrops.” NCT06659549 ↗ |